11C-CHOLINE PET/CT IN RECURRENCE DETECTION IN SURGICALLY TREATED PROSTATE CANCER PATIENTS WITH LOW PSA LEVEL

Aslanidis I.P.1, Pursanova D.M.1, Mukhortova O.V.1, Katunina T.A.1, Shirokorad V.I.2,   Roshchin D.A.3

Purpose. To evaluate the usefulness of 11C-Choline PET/CT in patients after radical prostatectomy with low PSA level for detection of PCa relapse.
1 - Bakoulev Scientific Center for
Cardiovascular Surgery.
2 - Moscow City
Oncology Hospital № 62.
3 - N. Lopatkin Scientific Research Institute of Urology and
Interventional Radiology.
Moscow, Russia.


 

Materials and methods. PET/CT was performed in 63 patients on PET/CT scanner (Biograph-64, Siemens) 10 min after injection of 11C-Choline (700–950 Mbq). The mean PSA value in the group was 0.94±0.51 (0.21–1.98) ng/ml, median – 0.93 ng/ml.

Results. Overall, 11C-Choline PET/CT detected PCa relapse in 30% (19/63) of cases. There was no statistical difference between PET-positive (n=19) and PET-negative (n=44) patients according to age, time to biochemical relapse after surgery, Gleason score and ongoing hormone therapy.

The detection rate of relapse according to 11C-Choline PET/CT showed correlation (p=0,007) with serum PSA: positive PET/CT results were obtained in 30% (19/63) patients with PSA<2,0 ng/ml, in 23% (12/53) – with PSA<1,5 ng/ml, in 17% (6/36) – with PSA<1,0 ng/ml, and in 20% (3/15) – with PSA<0,5 ng/ml.

PSA doubling time <6 months, stage >T3 and N1 were significantly associated with an increased probability of positive PET/CT findings (р<0,05 for all). All these parameters were found to be independent predictive factors for PET-positive result at simple linear regression analysis. The combination of mentioned predictors, except N1, was statistically significant in the prediction of a positive PET/CT at multiple linear regression analysis.

Local relapse was detected in 63% (12/19) patients, distant metastases – in 11% (2/19) cases, and both local and distant metastases – in 11% (2/19) cases.

Conclusions. 11C-Choline PET/CT was able to detect and correctly identify the localization of PCa relapse (local and distant) in 30% of patients with PSA<2,0 ng/ml, and therefore was useful in selection of further therapeutic approach. Pathological stage (>T3, N1), trigger PSA and short PSA doubling time were found to be significant predictors for PET-positive result and should be considered in patient selection for 11C-Choline PET/CT.

Keywords: prostate cancer recurrence, PET/CT, 11C-Choline, PSA, biochemical recurrence, choline.

 

Corresponding author: Pursanova D.M., Этот e-mail адрес защищен от спам-ботов, для его просмотра у Вас должен быть включен Javascript

 

For citation: Aslanidis I.P., Pursanova D.M., Mukhortova O.V., Katunina T.A., Shirokorad V.I.,   Roshchin D.A. 11c-choline pet/ct in recurrence detection in surgically treated prostate cancer patiens with low psa level REJR. 2016; 6 (2):60-71. DOI:10.21569/2222-7415-2016-6-2-60-71.


Received: 23.03.2016 Accepted: 04.04.2016